Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Non-Current Assets (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Other Non-Current Assets data on record, last reported at $4.9 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 178.87% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $4.9 million, up 178.87%, while the annual FY2025 figure was $4.9 million, 178.87% up from the prior year.
  • Other Non-Current Assets reached $4.9 million in Q4 2025 per RVMD's latest filing, down from $16.9 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $16.9 million in Q3 2025 and bottomed at $725000.0 in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $3.5 million, with a median of $2.7 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 406.54% in 2021, then crashed 42.53% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.7 million in 2021, then soared by 64.48% to $2.9 million in 2022, then rose by 6.09% to $3.0 million in 2023, then crashed by 42.53% to $1.7 million in 2024, then skyrocketed by 178.87% to $4.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $4.9 million in Q4 2025, $16.9 million in Q3 2025, and $3.9 million in Q2 2025.